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Platelets play a major role in acute ischaemic syndromes and peripheral vascular disease. They are involved in the
development and progression of atherosclerosis, native vessel and graft thrombosis. They have a central role in the
development of restenosis and reocclusion after peripheral percutaneous transluminal angioplasty. Antiplatelet therapy
has been shown to be beneficial in patients undergoing peripheral vascular surgery or radiological intervention. Yet current
routine therapy, namely aspirin and dipyridamole are limited in their mode of action and efficacy. Recent developments in
the understanding of platelet function has led to the development of new more potent drugs such as clopidogrel.
Combination of drugs and more specific investigation of individual platelet function may well result in improved bypass
and angioplasty patency rates. The results of proposed large randomised controlled trials on the role and safety of aspirin
and clopidogrel are awaited with interest. Given the importance of platelets in peripheral vascular disease highlighted in this
review, achieving an optimal safe anti-platelet effect for each patient with peripheral vascular disease should be the target of
future research.
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Introduction
Platelets play a fundamental, life-saving role in
haemostasis and blood clotting at sites of vascular
injury. However platelet activation and arterial throm-
bosis are implicated in various vascular events. A
large collaborative meta-analysis has shown that
aspirin or another antiplatelet drug reduces the inci-
dence of non-fatal myocardial infarction, non-fatal
stroke or vascular death in patients at increased risk
of occlusive vascular events.1 This implies that plate-
lets have a major role in atherosclerosis and its
complications in the coronary and cerebral vascular
systems. The same disease process however is respon-
sible for peripheral vascular disease and its complica-
tions, and platelets would also be expected to have a
major role at these sites. This is supported by the
findings of the Antiplatelet Trialists Collaboration2
who concluded that antiplatelet therapy reduces the
odds of graft or native arterial occlusion in patients
with peripheral vascular disease undergoing bypass
surgery or angioplasty. This article reviews the evi-
dence for the role of platelets in peripheral vascular
disease. A Medline and PreMedline literature search
(1966 to present) was performed to identify articles
relating to `` platelets'' in combination with `` peripheral
vascular disease'' and `` peripheral arterial disease''.
Further papers were identified by cross-referencing
from the reference lists of relevant major articles.
The Role of Platelets in the Development and
Progression of Atherosclerosis
The response-to-injury hypothesis, initially developed
by Virchow in the mid-19th century, still forms
the cornerstone of current understanding of the
development of atherosclerosis. This has been modi-
fied by many investigators over the last 50 years,
but has received a major contribution from Ross
and Glomset.3±5 Injury to the arterial endothelial cell,
resulting in endothelial cell dysfunction and loss, is
the first step in the process of atherosclerosis. This
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injury causes an immediate platelet response. Damage
to the endothelium and exposure of subendothelial
components, notably collagen6,7 and von Willebrand
factor,8 results in adherence of platelets to the
damaged vessel wall and subsequent activation. Col-
lagen interacts with glycoprotein Ia/IIa7 and vWF
interacts with GPIb/IX complex8 on the platelets
resulting in adhesion of the platelets to the suben-
dothelial matrix (Fig. 1). The binding also generates
an intracellular molecular signal, in a process called
`` outside-in'' signaling, which activates the GPIIb/IIIa
receptor. This is a surface integrin receptor within the
platelet membrane which undergoes a change in
shape on activation to express a high-affinity binding
site for fibrinogen9 (Fig. 1). This not only results in the
binding of fibrinogen but once fibrinogen is bound
`` outside-in'' signaling also occurs causing amplifica-
tion of the initial signal and further platelet activation.
This leads to further aggregation of platelets and
accumulation at the site of injury.
Platelet activation
Platelet activation also results in degranulation
which involves the discharge of platelet granule
contents such as the alpha-granule proteins beta-
thromboglobulin, platelet factor 4 and platelet derived
growth factor (PDGF) as well as adenosine diphos-
phate (ADP) from the platelet dense granules. PDGF
is believed to play an important part in the develop-
ment and progression of atherosclerosis and will be
discussed later on. ADP has been recognised as an
inducer of platelet aggregation since the early six-
ties.10,11 ADP plays a key role in platelet function
because it amplifies the platelet responses induced
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Fig. 1. Platelet adhesion and activation (Stages 1±3).
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by other platelet agonists.12 It also causes platelet
shape change and aggregation as well as generation
of thromboxane A2,
13 which is itself a potent
platelet activator.
P-selectin which is found in the membrane of alpha
granules in resting platelets14 rapidly appears in the
outer membrane once activation occurs. This serves as
a receptor for oligosaccharides within the membranes
of monocytes and polymorph neutrophils causing
such cells to adhere locally.15±17 The adhesion of
monocytes on the lumenal surface is followed by
migration across the endothelium and accumulation
within the intima.18 Here the monocytes are converted
to activated macrophages which take up lipoprotein
particles and become foam cells18 contributing to the
very early stage of atherosclerosis, the fatty streak.
Activation of the coagulation cascade
One of the early events after endothelial cell disrup-
tion is activation of the coagulation cascade with
resultant generation of thrombin at the site of damage.
This leads to further platelet activation and aggrega-
tion as well as the production of fibrin. Thrombin
activates platelet aggregation at much lower concen-
trations than those needed to produce its coagulant
effect.19 It binds to two protease-activated receptors
termed PAR1 and PAR4.20 Through these receptors,
thrombin activates phospholipase C which hydrolyses
phosphatidylinositol 4,5 bisphosphate (PIP2) into
inositol triphosphate (IP3) and diacylglycerol (DAG).
IP3 causes mobilisation of calcium stores which in turn
activates phospholipase A2 which leads to the pro-
duction of arachidonic acid (Fig. 2). Cyclo-
oxygenase 1 catalyses the synthesis of thromboxane
A2 from arachidonic acid in platelets leading to fur-
ther platelet activation and aggregation. Aspirin
exerts its anti-platelet effect by inhibiting cyclo-
oxygenase thus preventing the synthesis of thrombox-
ane A2. DAG, the other product of PIP2 hydrolysis,
stimulates protein kinase C (Fig. 3) which mediates
various platelet responses most important of which is
activation of the fibrinogen receptor GPIIb/IIIa.
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Fig. 2. Thrombin-induced platelet activation via IP3 pathway (Stages 1±7).
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Proliferation of smooth muscle cells
Proliferation of smooth muscle cells is an initial and
very important feature in the pathogenesis of athero-
sclerosis.21,22 PDGF, whose major source is circulating
platelets, is a major mitogen for various cells, includ-
ing the smooth muscle cell.23,24 PDGF also acts as a
chemoattractant and is believed to be essential for the
migration of the smooth muscle cell into the intima.25
Smooth muscle cells express PDGF receptors on their
surface. Following the stimulation of these receptors
by exogenous PDGF, smooth muscle cells commence
proliferation and synthesis of a PDGF-like protein
thus further stimulating mitosis.26
In baboons made chronically homocystinemic,
endothelial desquamation was accompanied by
marked smooth-muscle proliferation.27 Homocystine-
mia, which may result in premature atherosclerosis in
humans, is associated with increased production of
Thromboxane A2 by platelets28 and subsequent plate-
let activation and aggregation. In a separate group of
baboons treated with dipyridamole however,
although there was a similar degree of endothelial
desquamation, no smooth-muscle lesions developed,
providing evidence of a relation between endothelial
injury, platelet adhesion and smooth muscle prolifer-
ation.27 Similarly by using antiplatelet serum to make
rabbits thrombocytopenic, the development of such
lesions after balloon injury has been prevented.29
Development of atherosclerosis
Evidence for the role of platelets in the development
of atherosclerosis comes from observations in patients
with diabetes mellitus. Diabetes is one of the major
risk factors for peripheral vascular disease. Most stu-
dies have shown that platelets from patients with
diabetes show a hypersensitivity to aggregating
agents.30±32 There is also evidence to indicate
increased release of alpha granule contents in vivo in
diabetic patients and increased mitogenic effect of
released factors.33 Decreased levels of PDGF within
platelets in diabetics suggests increased release of
alpha granules in this group of patients.34 Platelets
from diabetics also show enhanced activity of the
arachidonate pathway and increased prostaglandin
and thromboxane A2 formation.
32,35 Fibrinogen
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Fig. 3. Thrombin mediated platelet activation via DAG pathway (Stages 1±6).
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binding to platelets from diabetic subjects is also
enhanced compared to platelets from control sub-
jects.36 The increased platelet activity correlates with
the enhanced vascular disease in the diabetic
population.
Our own group has shown, using whole blood flow
cytometry, that P-selectin expression on platelets as
well as platelet fibrinogen binding is increased in
patients with peripheral vascular disease (work sub-
mitted for publication). This suggests that platelet
activation is enhanced in patients with peripheral
vascular disease compared to healthy controls.
The Role of Platelets in Thrombosis in
Native Vessels
Thrombosis often occurs at sites of atherosclerotic pla-
que resulting in acute ischaemia of the lower limb and
potentially thromboembolic episodes. Local platelet
thrombosis occurs as a result of activation of platelets
due to higher shear stress or more commonly fissuring
or ulceration of the plaque. Shear force is directly
proportional to flow velocity and is inversely propor-
tional to the third power of the diameter of the vessel.
Thus shear force is higher at sites of stenosis induced
by atherosclerotic plaque which tends to develop at
sites where major arteries branch or curve. Shear-
induced platelet aggregation is initiated by binding
of soluble vWF to platelet GPIb.37 Once a threshold
shear is reached, the vWF-GPIb interaction triggers
intracellular signaling that leads to platelet activation
and binding of fibrinogen to GPIIb/IIIa with subse-
quent platelet aggregation.38
The lipid core of advanced atheromatous lesions is
rich in tissue factor39 which is probably generated by
activated macrophages within the plaque. Disruption
of these advanced plaques with exposure of their lipid
cores triggers the formation of thrombus six times
larger than those generated by other components of
the arterial wall.39 Tissue factor initiates the coagula-
tion cascade by interacting with factor VII and subse-
quently activating factor X.40 The end product of the
coagulation cascade is thrombin which is itself a
potent inducer of platelet aggregation. Toschi and col-
leagues have shown a positive correlation between
quantitative platelet deposition and tissue factor in
human arterial segments exposed to high shear stress
in vitro.40 The deposition of platelets and formation of
platelet aggregates leads to the occlusion of vessels.
There is strong evidence to suggest that thrombus
formation stimulates smooth muscle cell migration
and proliferation through the action of a number of
factors liberated from the platelet rich thrombus,
particularly platelet derived growth factor.41 Mural
thrombi are later incorporated into the vessel wall
resulting in organised thrombi and subsequent
luminal stenosis.
The important role of platelets in the progression of
peripheral arterial occlusive disease was further
demonstrated in a double-blind controlled trial of
300 patients with peripheral arterial occlusive disease.
These patients were followed up for two years with
angiography. Administration of antiplatelet drugs
(aspirin with or without dipyridamole) significantly
reduced the progression of disease compared to
placebo.42
The Role of Platelets in Occlusion of
Bypass Grafts
Deposition of platelets plays an important role in fail-
ure of synthetic grafts, in causing thrombosis, throm-
boembolic phenomena or promoting late graft failure
through the stimulation of anastomotic neointimal
hyperplasia.43
Demonstration of platelet deposition
The deposition of platelets on prosthetic grafts has
been demonstrated in several ex-vivo and in-vivo
animal models.44±48 In humans, Goldman and collea-
gues49 showed that platelets deposited and accumu-
lated on Dacron aortofemoral grafts by using
111-indium labelled autologous platelets. Patients
who had undergone bypass procedures were followed
up for up to 9 years. All grafts, regardless of age
accumulated platelets and even up to 9 years post-
grafting Dacron grafts continued to demonstrate
platelet accumulation, although at a reduced rate.
Platelet labelling has also been used to compare plate-
let accumulation in saphenous vein, polytetrafluoro-
ethylene (PTFE) and Dacron femoropopliteal grafts.50
Isotope emissions over the graft were measured and
graft thrombogenicity calculated as the daily rise over
7 days. The results were expressed as a ratio of counts
over the graft compared to the contralateral leg, mean
thrombogenicity index. This was greatest in the
Dacron grafts, followed by PTFE. Saphenous vein was
markedly less thrombogenic than either prosthetic
graft, which clearly corresponds with clinical
data on femoropopliteal bypass graft patency.51
The marked differences observed in platelet
accumulation within prosthetic and venous grafts
and subsequent patency rates is due in part to the
inherent anti-platelet characteristics of endothelium.
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Komori and colleagues showed that the presence of
endothelium induces relaxation in response to
aggregating platelets in porcine femoral veins.52
Endothelium is a source of PGI2 which is a potent
activator of adenylate cyclase. The resultant increase
in cAMP causes platelet inhibition. PGI2 also inhibits
PDGF released from platelets even at very low doses.
Nitric oxide (NO) produced by the endothelium is a
potent activator of guanylate cyclase. Platelet acti-
vation is down-regulated by NO, and PGI2 and NO
act synergistically to inhibit platelet aggregation.53 NO
has also been shown to cause disaggregation of pre-
formed platelet aggregates.54 Both PGI2 and NO are
also potent vasodilators.55 Activated platelets them-
selves produce and release various compounds, such
as ADP, ATP, and serotonin, that in the presence of
vascular endothelium induce self-regulatory mechan-
isms. These factors stimulate endothelial cells through
receptor-dependent mechanisms which in turn acti-
vate phospholipase C. This induces an increase in
cytosolic free calcium concentration and this activates
both NO synthase and phospholipase A2, resulting in
increased production of NO and PGI2. Thus in the
presence of functional endothelium activated platelets
also initiate the production of factors that limit platelet
activation and vasoconstriction.
Effect of antiplatelet treatment on platelet deposition
Exposure to prosthetic material or denudation of the
venous endothelium during harvesting of a vein are
associated with platelet adhesion and aggregation.
This may be amplified by technical factors that reduce
graft flow, such as intact venous valves, anastomotic
stricture or poor run off leading to thrombosis. Platelet
deposition at sites of endothelial denudation at the
time of surgery is followed by migration of smooth
muscle cells into the intima and proliferation of these
cells in response to various factors, particularly PDGF.
Later, synthesis and deposition of extracellular matrix
by activated smooth muscle cells leads to a progres-
sive increase in intimal fibrosis and a reduction in
cellularity.56,57
In a randomised double-blind controlled trial,
patients undergoing femoro-popliteal bypass surgery
received either placebo or a combination of aspirin
and dipyridamole in the peri-operative period.58
Using a platelet labelled technique the graft load of
platelet aggregation was measured at 7 days post-op.
The combination of aspirin and dipyridamole signifi-
cantly reduced platelet accumulation in Dacron and
PTFE grafts. Vein grafts, however, accumulated very
few labelled platelets and the combination of aspirin
and dipyridamole had no further effect on platelet
accumulation.
This would only be of clinical importance if
increased platelet deposition measured shortly after
surgery was related to subsequent graft thrombosis.
The relationship between platelet deposition and
patency in small calibre arterial graft in patients
undergoing femoropopliteal bypass has been investi-
gated by Goldman and colleagues.59 The Dutch
Bypass Oral anticoagulants or Aspirin study showed
that aspirin was better for the prevention of non-ven-
ous graft occlusion.60 In a double-blind randomised
controlled trial patients undergoing femoropopliteal
bypass received either aspirin and dipyridamole or
placebo.59 In the prosthetic grafts the combination of
aspirin and dipyridamole not only reduced platelet
accumulation at the graft site but was also associated
with a significantly increased 1-year patency.
Further studies, including seven randomised con-
trolled trials, have investigated the effect of antiplate-
let agents in prevention of graft occlusion after
infrainguinal bypass (Table 1). Six of the seven rando-
mised controlled trials have supported the findings of
Goldman and colleagues. The 1 year cumulative
patency rate for above-knee PTFE grafts was signifi-
cantly higher in patients treated with aspirin alone or
aspirin and dipyridamole compared to placebo in a
randomised double-blind trial.61 In another prospect-
ive randomised double blind study the combination
of aspirin and dipyridamole significantly increased
Dacron graft patency over the first 24 months
compared to placebo.62 Ticlopidine, a thienopyridine,
was found to be significantly more effective at main-
taining femoropopliteal or femorotibial vein graft
patency than placebo in a randomised double-blind
controlled trial.63 The Antiplatelet Trialists' Collabor-
ation concluded in their overview of randomised trials
that antiplatelet therapy produced an absolute
reduction in the risk of peripheral artery or graft
occlusion in patients undergoing peripheral bypass
or angioplasty.2
In a randomized multicentre trial intravenous
dextran-40 was shown to be effective in maintaining
early patency in difficult lower extremity bypasses
(i.e. femoropopliteal bypass with poor runoff using
autologous vein, femoropopliteal bypasss using pros-
thetic grafts, and single or sequential bypasses to
infrapopliteal arteries).64 Shoenfeld and colleagues
later showed that this was due to the antiplatelet effect
of dextran-40 and not simply due to plasma volume
expansion.65 Using indium labeled platelets low
molecular weight dextran was found to significantly
reduce platelet deposition onto graft surfaces through
a direct antiplatelet effect.66 The precise mechanism of
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action of dextran-40 is not entirely clear but one pro-
posed mechanism is through a reduction in vWF,
which is the ligand for GPIb on the platelet surface.67
The consistent improvement in patency rates asso-
ciated with adjuvant antiplatelet therapy supports the
central role platelets play in the two processes leading
to vascular graft failure: thrombosis and intimal
hyperplasia.68
The Role of Platelets in Restenosis and
Occlusion after Percutaneous Transluminal
Angioplasty
Platelet adhesion is the first mechanical event that
occurs after endothelial denudation induced by angio-
plasty. This is followed by the release of PDGF which
is involved in initiating the migration of medial
smooth muscle cells into the intima and their subse-
quent proliferation.69 In a rat model of balloon angio-
plasty, PDGF greatly increased the intimal thickening
and the migration of smooth muscle cells from the
media to the intima during the first 7 days after arter-
ial injury.25 The final stage in the development of the
lesion of intimal hyperplasia is replication of smooth
muscle cells and secretion of extracellular matrix.70
Initial success rates of peripheral percutaneous
transluminal angioplasty (PTA) have reached over
90% but subsequent failure rates remain high. The
4 year primary patency rates following PTA for
aortoiliac occlusive disease has been reported in a
meta-analysis to be 65% for stenoses and 54% for
occlusions.71 For femoropopliteal disease the patency
rate four years after angioplasty is reported as 52%.72
Early failure is due to occlusion following thrombosis
and spasm and delayed failure occurs as a result of
restenosis secondary to intimal hyperplasia. Both pro-
cesses are believed to be platelet dependent.73
Angioplasty induces significant damage to the
artery. In vivo analysis of human iliac stenoses by
intravascular ultrasound immediately after angio-
plasty has shown plaque fractures and `` compression''
of atherosclerotic plaque.74 Cracking, splitting or dis-
ruption of the intima and plaque as well as dehiscence
of the intima and the plaque from the underlying
media is observed after angioplasty.75 The damage
induced results in adhesion, activation and aggrega-
tion of platelets at the site. 51-Cr labeled platelets were
used in an animal model to demonstrate a rapid rise in
platelets at the site of angioplasty within 30 min and
reaching a peak at 2 h.76 Thus the vast majority of
platelet adhesion occurs within 2 h of angioplasty.
This study also showed that the more marked the
intimal dissection induced by angioplasty the greater
the degree of platelet accumulation. In humans under-
going PTA, 111-indium labeled platelets have been
shown to accumulate at the site of angioplasty.
Increased radioactivity at the site persists even 48 h
later.77 Miller and colleagues used a monoclonal Fab0
antibody (S12) that is specific for the platelet mem-
brane glycoprotein (GMP140) expressed during plate-
let activation and have shown that platelets are
activated at the site of angioplasty. In complicated
procedures platelet activation was higher compared
to uncomplicated procedures.78 TXA2 which is pro-
duced by activated platelets increases twofold after
peipheral angioplasty.79
Table 1. Randomised controlled trials of antiplatelet agents in prevention of graft occlusion after infrainguinal bypass.
Author/year No. of
patients
Type of bypass Drugs Graft
material
Follow-up/
months
Graft patency
Green 198261 49 AK fempop (53);
BK (47)
A975, AD225, P PTFE 12 Above-knee grafts significantly
better with A and AD
compared to P (p 0.05)
Goldman 198359 67 AK fempop (34);
BK (33)
A900D225, P PTFE (37),
Dacron (16)
12 Better with AD compared
to P (p5 0.05)
Kohler 198490 100 AK Fem-pop (37);
BK (45), Crural (18)
A975D225, P Vein (70),
PTFE (30)
24 No significant difference
between AD and P
Donaldson 198591 65 AK Fem-pop (68);
BK (32)
A990D225, P Dacron 12 Better with AD compared
to P (p5 0.05)
Sheehan 198762 65 AK fem-pop (73) A990D225, P Dacron 60 Better with AD compared to P
in first 24 months (p5 0.05)
McCollum 199192 549 AK Fem-pop (41),
BK (59)
A600D300, P Vein 36 Better with AD compared to
P but not statistically
significant (p 0.43)
Becquemin 199762 243 BK femoropop or
femorotibial (243)
T500, P Vein 24 Significantly better with T
compared to P (p 0.02)
AK above-knee; BKbelow-knee; A aspirin; DDipyridamole; Pplacebo; PTEpolytetrafluoroethylene; TTiclopidine. The
number beside the abbreviation refers to the dose in milligrams per day.
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A markedly increased platelet accumulation at the
site of angioplasty, measured using labeled platelets,
was found to be strongly predictive of acute angio-
plasty occlusion.80 Patients who went on to develop
restenosis were also observed to have higher platelet
accumulation at the site of angioplasty although this
difference failed to reach statistical significance. A
similar trend was seen in the relationship between
high early platelet uptake at angioplasty sites and
subsequent failure in a study by Poskitt and collea-
gues.77 However only 20 patients were included in
this study and no clear relationship was
demonstrated.
Inhibition of platelet adhesion using aurintricar-
boxylic acid (ATA), a substance that inhibits platelet
glycoprotein Ib-vonWillebrand factor interaction, has
been shown to reduce neointimal hyperplasia after
balloon arterial injury in a rabbit model.81 This sug-
gests that platelet adhesion is an important step in the
development of neo-intimal hyperplasia. In a rando-
mised controlled trial of 199 patients, the combination
of high dose aspirin and dipyridamole significantly
reduced restenosis or occlusion 6 months after percu-
taneous angioplasty compared to a placebo group.82
In another double blind study the combination of
dipyridamole and aspirin proved to be slightly more
effective than aspirin alone in preventing reocclusion
after percutaneous angioplasty83 (Table 2). This sug-
gests that a more potent anti-platelet effect is more
effective at preventing restenosis after angioplasty.
The use of endovascular stents is also associated
with platelet adhesion, thrombosis and occlusion.
Using an animal model Parsson and colleagues
showed that at the site of arterial stenting there is an
increase in platelet deposition.84 Stent surface coating
and texture appears to play a role in platelet acti-
vation85 and for this reason various types of coatings
have been developed in attempts to reduce the
thrombogenicity of stents.86,87
Conclusions
Platelets play a major role in the development and
progression of atherosclerosis, in venous and pros-
thetic bypass graft patency and in restenosis and
occlusion after peripheral percutaneous transluminal
angioplasty. There is evidence that anti-platelet treat-
ment improves the results of bypass grafting and
angioplasty. To date aspirin and dipyridamole have
been the two main anti-platelet drugs investigated in
this context. These drugs however have limitations in
terms of mode of action and in the case of aspirin
possible resistance. A recent study has suggested
that only 40% of male patients with claudication
show the expected effect of aspirin.88 Aspirin only
inhibits platelets through the cylo-oxygenase pathway
and the mechanism of action of dipyridamole is still
controversial. Current routine anti-platelet strategies
are therefore sub-optimal. Improved anti-platelet effi-
cacy may be achieved by combining aspirin with the
ADP receptor inhibitor clopidogrel. The Clopidogrel
in Unstable Angina to Prevent Recurrent Events
(CURE) trial has shown that the combination of clopi-
dogrel with aspirin results in a 20% relative risk
reduction in cardiovascular death, non-fatal myocar-
dial infarction and stroke in patients with unstable
angina compared to aspirin alone with minimal
increased side effects.89 The potential combined effect
of aspirin and clopidogrel has not been investigated
in peripheral vascular disease until now. Two
large multicentre studies investigating the effect of
this combination of drugs following peripheral percu-
taneous transluminal angioplasty and peripheral
bypass grafting are about to commence. Given the
importance of platelets in peripheral vascular disease
highlighted in this review, achieving an optimal safe
anti-platelet effect for each patient with peripheral
vascular disease should be the target of future
research.
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